Thursday, April 10, 2025

Technology | 2019.04.24

NeuroSigma Announces FDA Clearance of Monarch eTNS System as First Non-Drug Treatment for Pediatric ADHD

LOS ANGELES, April 23, 2019 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders today announced that its Monarch® eTNS® System...

 

For more information, please visit
https://www.prnewswire.com:443/news-rele[...]-pediatric-adhd-300837050.html

You need to login to post comments.

Feed last updated 2025/04/30 @8:04 AM

0 COMMENTS:

Follow us on Follow Us on Facebook Follow Us on Twitter
©2006 Translations News